普氏粪杆菌
微生物群
失调
癌症
免疫系统
人体微生物群
癌变
细菌
生物
hirae肠球菌
人类微生物组计划
阿克曼西亚
微生物学
免疫学
癌症研究
生物信息学
肠道菌群
乳酸菌
肠球菌
遗传学
作者
Anna Grenda,Paweł Krawczyk
标识
DOI:10.1007/s00253-021-11125-0
摘要
Currently, increasing attention cancer treatment has focused on molecularly targeted therapies and more recently on immunotherapies targeting immune checkpoints. However, even such advanced treatment may be ineffective. The reasons for this are sought, inter alia, in the human microbiome. In our intestines, there are bacteria that are beneficial to us, but pathogenic microorganisms may also be present. Microbial imbalance (dysbiosis) is now perceived as one of the gateways to cancer. However, it is feasible to use bacteria and their metabolites to restore the natural, beneficial microbiome during oncological treatment. Akkermansia mucinifila, Enterococcus hirae, or Faecalibacterium prausnitzii are bacteria that exhibit this beneficial potential. Greater benefits of therapy can be observed in cancer patients enriched in these bacterial species and treated with anti-PD-1, anti-PD-L1, or anti-CTLA-4 monoclonal antibodies. In this review, we present issues related to the role of bacteria in carcinogenesis and their therapeutic potential supporting modern anti-cancer therapies.Key Points• Bacteria can be directly or indirectly a cancer trigger.• Bacterial metabolites regulate the pathways associated with carcinogenesis.• Intestinal bacteria activate the immune system to fight cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI